- Home
- MOB vs ANEB Comparison
MOB vs ANEB Comparison
Compare MOB & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MOB | ANEB |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.0M | 96.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MOB | ANEB |
|---|---|---|
| Price | $8.01 | $2.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 335.5K | 16.6K |
| Earning Date | 08-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,826,361.00 | N/A |
| Revenue This Year | $142.38 | N/A |
| Revenue Next Year | $99.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $0.80 |
| 52 Week High | $11.02 | $3.42 |
Technical Indicators
Market Signals| Indicator | MOB | ANEB |
|---|---|---|
| Relative Strength Index (RSI) | 59.21 | 39.70 |
| Support Level | $5.88 | $2.26 |
| Resistance Level | $7.56 | $2.41 |
| Average True Range (ATR) | 0.83 | 0.10 |
| MACD | 0.23 | -0.00 |
| Stochastic Oscillator | 91.41 | 17.86 |
Price Performance
Historical ComparisonAbout MOB Mobilicom Limited
Mobilicom Ltd is a provider of cybersecurity and smart solutions for drones, robotics & autonomous platforms. As a high-tech company, it designs, develops, and delivers smart solutions targeting global drone, robotics, and autonomous system manufacturers. Its products include OS3 Platform Software, ICE Cybersecurity Software, MCU Mesh Networking, SkyHopper Datalinks, Mobile Ground Control Stations and System Engineering Services.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.